First Manhattan’s Acceleron Pharma XLRN Stock Holding History

First Manhattan’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16	Closed	-$2K	–	1752
2021 Q3	$2K	Buy	+16	New	+$2.09K	﹤0.01%	1533
2018 Q3	–	Sell	-155,600	Closed	-$7.55M	–	1465
2018 Q2	$7.55M	Hold	155,600	–	–	0.04%	216
2018 Q1	$6.08M	Sell	155,600 -164,400	-51%	-$6.99M	0.03%	229
2017 Q4	$13.6M	Sell	320,000 -6,000	-2%	-$225K	0.07%	166
2017 Q3	$12.2M	Sell	326,000 -2,500	-0.8%	-$86.8K	0.07%	171
2017 Q2	$9.98M	Buy	328,500 +128,500	+64%	+$3.72M	0.06%	178
2017 Q1	$5.29M	Buy	200,000 +150,000	+300%	+$3.95M	0.03%	235
2016 Q4	$1.28M	Buy	+50,000	New	+$1.58M	0.01%	388

First Manhattan's XLRN Position: Q4 2021 in Review

First Manhattan sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 16 shares — an estimated $2K sold.

First Manhattan first reported a position in XLRN in Q4 2016 and held it in 8 quarters. The position peaked at $13.6M in Q4 2017. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

First Manhattan reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
First Manhattan sold 16 Acceleron Pharma shares in Q4 2021, an estimated $2K.
First Manhattan first reported a position in Acceleron Pharma in Q4 2016 and held it in 8 quarters.
First Manhattan's Acceleron Pharma position peaked at $13.6M in Q4 2017.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on First Manhattan's 13F filing for Q4 2021, filed 14 Feb 2022.